Citation:Luo Y, Cui HP, Liu Y, Chen L. Metabolomics and biomarkers in ocular matrix: beyond ocular diseases. Int J Ophthalmol 2020;13(6):991-1003,doi:10.18240/ijo.2020.06.21
Metabolomics and biomarkers in ocular matrix: beyond ocular diseases
Received:February 19, 2020  Revised:March 23, 2020
Email this Article  Add to Favorites  Print
DOI:10.18240/ijo.2020.06.21
Key Words:metabolomics  biomarkers  ocular matrix  ocular diseases  diagnosis
Fund Project:Supported by the National Natural Science Foundation of China (No.81872980; No.81673556); the Guangdong Basic and Applied Basic Research Special Fund (No.2017A030313753); the Administration of Traditional Chinese Medicine of Guangdong Province (No.20192055).
           
AuthorInstitution
Yun Luo School of Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou , Guangdong Province, China
Hong-Pei Cui Department of Ophthalmology, Henan Provincial People’s Hospital, Zhengzhou , Henan Province, China
Yi Liu School of Chinese Medicine, Southern Medical University, Guangzhou , Guangdong Province, China
Lei Chen School of Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou , Guangdong Province, China
Hits: 130
Download times: 18
Abstract:
      According to the recent report, there are 870 million people suffer from ocular diseases worldwide. The present approaches for diagnosis are morphological examination, imaging examination and immunological examination, regrettably, they lack of sensitivity and difficult to make a definite diagnosis in the early stage. Systemic biology as an effective method has been used in clinical diagnosis and treatment for diseases, especially metabolomics which is more attractive with high sensitivity and accuracy. Although previous researches had been confirmed that endogenous metabolites in the ocular matrix play a crucial role in the progress of diseases related diseases, the standard protocols and systematic summary about the biomarker researches based on ocular matrix has not been established. This review article highlights the pretreatment for ocular matrix and the new biomarkers expressed by the eye diseases, expected to promote the application of biomarkers in the diagnosis and treatment of eye diseases.
PMC FullText Html:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270262/
Supplementary Material
PDF Fulltext  Download reader  HTML Fulltext   View/Add Comment